TR201909997T4 - 5-HT4 reseptör agonistleri olarak amid bileşikleri. - Google Patents

5-HT4 reseptör agonistleri olarak amid bileşikleri. Download PDF

Info

Publication number
TR201909997T4
TR201909997T4 TR2019/09997T TR201909997T TR201909997T4 TR 201909997 T4 TR201909997 T4 TR 201909997T4 TR 2019/09997 T TR2019/09997 T TR 2019/09997T TR 201909997 T TR201909997 T TR 201909997T TR 201909997 T4 TR201909997 T4 TR 201909997T4
Authority
TR
Turkey
Prior art keywords
compounds
receptor agonists
amide compounds
relates
present
Prior art date
Application number
TR2019/09997T
Other languages
English (en)
Inventor
Nirogi Ramakrishna
Karbhari Shinde Anil
Rasheed Mohammed Abdul
Keshari Saraf Sangram
Bogaraju Narsimha
Subramanian Ramkumar
Jayarajan Pradeep
Bhyrapuneni Gopinadh
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of TR201909997T4 publication Critical patent/TR201909997T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Mevcut buluş, bunların stereoizomerleri ve farmasötik olarak kabul edilebilir tuzları dahil olmak üzere formülün (I) bileşikleri ile ilgilidir. Bu buluş aynı zamanda bu tür bileşiklerin yapılması yöntemleri ve bu tür bileşikleri içeren farmasötik bileşimler ile ilgilidir. Bu buluşun bileşikleri, 5-hidroksitriptamin 4 (5-HT4) reseptörü ile ilgili olan çeşitli bozuklukların tedavisinde faydalıdır.
TR2019/09997T 2015-02-13 2016-01-07 5-HT4 reseptör agonistleri olarak amid bileşikleri. TR201909997T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13

Publications (1)

Publication Number Publication Date
TR201909997T4 true TR201909997T4 (tr) 2019-07-22

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09997T TR201909997T4 (tr) 2015-02-13 2016-01-07 5-HT4 reseptör agonistleri olarak amid bileşikleri.

Country Status (29)

Country Link
US (1) US9957257B2 (tr)
EP (1) EP3265459B1 (tr)
JP (1) JP6487564B2 (tr)
KR (1) KR101966576B1 (tr)
CN (1) CN107406434B (tr)
AU (1) AU2016217461B2 (tr)
BR (1) BR112017017275A2 (tr)
CA (1) CA2975973C (tr)
CY (1) CY1121898T1 (tr)
DK (1) DK3265459T3 (tr)
EA (1) EA034618B1 (tr)
ES (1) ES2734734T3 (tr)
HR (1) HRP20191179T1 (tr)
HU (1) HUE045667T2 (tr)
IL (1) IL253848B (tr)
LT (1) LT3265459T (tr)
MA (1) MA41633B1 (tr)
MD (1) MD3265459T2 (tr)
ME (1) ME03430B (tr)
MX (1) MX368214B (tr)
NZ (1) NZ734400A (tr)
PL (1) PL3265459T3 (tr)
PT (1) PT3265459T (tr)
RS (1) RS59066B1 (tr)
SG (1) SG11201706501VA (tr)
SI (1) SI3265459T1 (tr)
TR (1) TR201909997T4 (tr)
WO (1) WO2016128990A1 (tr)
ZA (1) ZA201705292B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2780015T3 (pl) 2011-11-18 2017-06-30 Heptares Therapeutics Limited Agonisty receptora muskarynowego M1
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545092C (en) 2003-11-24 2010-08-17 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
DK1856114T3 (en) 2005-02-25 2014-11-17 Raqualia Pharma Inc Benzisoxazol-DERIVATIVES
US7906532B2 (en) 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
TW200732327A (en) 2005-10-28 2007-09-01 Glaxo Group Ltd Novel compound
GB0525661D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
US9079894B2 (en) * 2011-09-19 2015-07-14 Suven Life Sciences Ltd Heteroaryl compounds as 5-HT4 receptor ligands
CA2907620C (en) * 2013-03-20 2018-03-13 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
KR101824154B1 (ko) * 2013-12-16 2018-03-14 수벤 라이프 사이언시스 리미티드 5-ht4 수용체 작용제로서 인다졸 화합물

Also Published As

Publication number Publication date
IL253848B (en) 2018-01-31
MX368214B (es) 2019-09-24
MA41633A (fr) 2019-05-15
CN107406434B (zh) 2020-09-11
LT3265459T (lt) 2019-08-26
PL3265459T3 (pl) 2019-09-30
EP3265459A1 (en) 2018-01-10
JP2018509396A (ja) 2018-04-05
AU2016217461B2 (en) 2018-07-05
RS59066B1 (sr) 2019-09-30
CA2975973C (en) 2019-07-16
PT3265459T (pt) 2019-07-17
MD3265459T2 (ro) 2019-09-30
EP3265459B1 (en) 2019-05-15
DK3265459T3 (da) 2019-07-15
JP6487564B2 (ja) 2019-03-20
AU2016217461A1 (en) 2017-09-14
US9957257B2 (en) 2018-05-01
WO2016128990A1 (en) 2016-08-18
MA41633B1 (fr) 2019-07-31
HUE045667T2 (hu) 2020-01-28
CY1121898T1 (el) 2020-10-14
EA201791829A1 (ru) 2018-05-31
BR112017017275A2 (pt) 2018-04-17
NZ734400A (en) 2018-03-23
HRP20191179T1 (hr) 2019-10-04
MX2017010348A (es) 2018-06-07
ZA201705292B (en) 2019-06-26
EA034618B1 (ru) 2020-02-27
ES2734734T3 (es) 2019-12-11
IL253848A0 (en) 2017-09-28
KR101966576B1 (ko) 2019-04-05
ME03430B (me) 2020-01-20
KR20170117167A (ko) 2017-10-20
SI3265459T1 (sl) 2019-09-30
CA2975973A1 (en) 2016-08-18
CN107406434A (zh) 2017-11-28
SG11201706501VA (en) 2017-09-28
US20180051011A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201691302A1 (ru) Новые гетероциклические соединения
TR201909997T4 (tr) 5-HT4 reseptör agonistleri olarak amid bileşikleri.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
EA201992679A1 (ru) N-замещенные индольные производные
EA201700042A1 (ru) Соединения имидазопиридазина
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
TR201819805T4 (tr) Flavaglin türevleri̇.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
CY1123185T1 (el) Παραγωγα ινδολιου
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора